Business
Admission to AQSE and First Day of Dealings
Admission to AQSE and First Day of Dealings.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n \n This announcement contains Inside Information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n 14 November 2022\n EDX Medical Group Plc\n (Formerly TECC Capital Plc)\n (\"the Company\")\n Admission to trading on AQSE and First Day of Dealings\n Highlights\n \n Acquisition of EDX Medical Limited for £12m completed\n Placing of new shares at 6 pence per share completed raising £1.2m\n New Board appointed\n Change of name to EDX Medical Group Plc completed\n \n Further to its announcement on 26 October 2022, the Company, now renamed EDX Medical Group Plc (“EDX Medical”), has today completed its acquisition of EDX Medical Limited. The Company (TIDM: EDX), which develops digital diagnostic products and services for use in testing for cancer, heart disease, neurology and infectious diseases, is pleased to announce that 250,833,333 ordinary shares of 1 pence each (“Ordinary Shares”) are today being admitted to trading on the Access Segment of the AQSE Growth Market (\"Admission\").\n In connection with Admission, the Company has raised £1.2 million through a placing of 20,000,000 Ordinary Shares at a price of 6 per share.\n In addition, the appointment of the new Board, comprising Jason Holt as Chairman, Dr Michael Hudson as Chief Executive, Professor Sir Christopher Evans, OBE, as Chief Scientific Officer and Professor Trevor Jones as a Non-executive Director has taken effect and the former Directors, Sandy Barblett, John Taylor and Donald Stewart have stepped down from the Board with effect from Admission.\n Further details of each of members of the new Board are set out in the Company’s announcement of 26 October 2022 and can be found in the Company’s Admission Document which was published on the same day.\n EDX Medical Ltd was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience in the sector, specialising in cancer treatments and diagnostics.\n Jason Holt, Chairman, stated: “We are proud to be bringing EDX Medical to the AQSE Growth Market today as an important part of our strategy to...